As trilogue negotiations on the reform of the EU pharmaceutical legislation continue after the summer, the Alliance calls on EU policymakers to strike the right balance between improving patient access to medicines, addressing unmet medical needs, and ensuring a sustainable, innovative healthcare system. The revision of the EU pharmaceutical legislation is one of the most extensive reforms in over two decades. The BioMed Alliance stresses the need for legislation that enhances the availability, affordability, and accessibility of medicines across the EU, ensuring that research and innovation translate into real patient benefits.
BioMed Alliance urges decision-makers to:
- Clarify the definition of unmet medical needs to include quality of life and patient-reported outcomes.
- Address medicine shortages through stronger prevention plans and notification requirements.
- Taking a balanced approach in conflict-of-interest policies
- Enhance research and innovation by supporting drug repurposing and ensuring funding transparency.
- Expand the Role of HERA
- Safeguard paediatric medicines by prioritising long-term patient outcomes
- Improve overall access to medicines for European patients
